Navigation Links
WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release
Date:7/22/2014

SHANGHAI, July 22, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the second quarter of 2014 after the New York Stock Exchange closes on Wednesday, August 13, 2014 (which will be Thursday morning, August 14, 2014 Shanghai time). The earnings release will be available on the investor relations section of the Company's website at http://www.wuxiapptec.com .

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 8:00 pm (Beijing/Shanghai/Hong Kong) on Thursday, August 14, 2014, to discuss the second-quarter 2014 financial results and recent business activities. The conference call may be accessed by calling: Mainland China

4001 200 539Hong Kong

800 905 927Singapore

800 616 3222United Kingdom

0800 015 9725United States

1855 298 3404United States -- New York (toll)

+1 631 5142 526Other countries (toll)

+65 6823 2299Conference ID

7388753 A telephone replay will be available two hours after the call's completion at:

Mainland China

4001 842 240Hong Kong

800 966 697Singapore

800 616 2127United Kingdom

0800 169 7301United States

1866 846 0868Conference ID

7388753 

A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at http://www.wuxiapptec.com.

About WuXi PharmaTechWuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For more information, please contact:

Ronald Aldridge
Director of Investor Relations
WuXi PharmaTech (Cayman) Inc.
Tel: +1-201-585-2048
Email: Ron_Aldridge@wuxiapptec.com
Web: http://www.wuxiapptec.com  


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
2. Industry Leading Pharmaceutical News Website in-Pharmatechnologist.com Refocused and Relaunched
3. WuXi PharmaTech Announces First-Quarter 2012 Results
4. Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
5. WuXi PharmaTech Announces Second-Quarter 2012 Results
6. WuXi PharmaTech Receives GLP Certificate from SFDA for Suzhou Toxicology Facility
7. WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics
8. WuXi PharmaTech and Open Monoclonal Technology Announce OmniRat(TM) Antibody Collaboration
9. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
10. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
11. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):